arrow_back Back to App

US-Made Drugs: Government Agencies to Prioritize Domestic Pharmaceutical Purchases

New rules require government agencies to purchase pharmaceuticals primarily manufactured in the United States. This aims to enhance the security of drug supplies and reduce reliance on foreign producers. Citizens may experience greater stability in access to essential medicines, especially during crises.
Key points
Government agencies must purchase drugs that are over 50% sourced, manufactured, and assembled in the U.S.
Exceptions apply if a drug is not sufficiently available from U.S. sources or during emergencies.
U.S. trade agreements will be modified to exclude essential medicines and medical countermeasures from certain coverages.
The provisions will take effect one year after the current emergency period ends.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_3683
Sponsor: Rep. Stauber, Pete [R-MN-8]
Process start date: 2021-06-01
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Securing America’s Pharmaceutical Supply Chain Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_3683.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-06-01.

What are the main provisions?

Key points include:

  • Government agencies must purchase drugs that are over 50% sourced, manufactured, and assembled in the U.S.
  • Exceptions apply if a drug is not sufficiently available from U.S. sources or during emergencies.
  • U.S. trade agreements will be modified to exclude essential medicines and medical countermeasures from certain coverages.
  • The provisions will take effect one year after the current emergency period ends.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Stauber, Pete [R-MN-8].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Trade.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Economy